<!DOCTYPE html>
<html manifest="manifest.manifest">
<head>
	<meta http-equiv=Content-Type content="text/html; charset=utf-8">
	<title>MRCG Clinical Guidelines</title>
	<meta name="viewport" content="width=device-width, initial-scale=1.0, minimum-scale=1.0, maximum-scale=2.0, user-scalable=1">
	<meta name=Generator content="Microsoft Word 14 (filtered)">
	<link rel="manifest" href="/manifest.json">	
<link rel="stylesheet" href="jquery.mobile-1.4.5.min.css" />
	<link rel="stylesheet" href="mystyle.css" />
	<script src="jquery-1.11.1.min.js"></script>
	<script src="jquery.mobile-1.4.5.min.js"></script>
	<script type="text/javascript" src="cordova.js"></script>
	<script>
	    		$(function(){
			$("[data-role='header'], [data-role='footer']").toolbar();
		});
  	  $(document).one('pagebeforecreate', function () {
	        $('input[data-type="search"]').val("");
	    	        $.get("panel.html", function (data2) {
            $.mobile.pageContainer.prepend(data2);
              $("[data-role=panel]").panel().enhanceWithin();
        }, "html");
	           $.get("header.html", function (data) {
      $.mobile.pageContainer.prepend(data);
      $("[data-role='header']").toolbar().enhanceWithin();
    }, "html");
    $.get("footer.html", function (data) {
      $.mobile.pageContainer.append(data);
      $("[data-role='footer']").toolbar().enhanceWithin();
    }, "html");
        $('.WordSection1').wrap('<div role="main" class="ui-content">');
        $('table').wrap('<div class="tableCont"></div>');
        $('img').wrap('<div class="tableCont"></div>');
        $.mobile.pageContainer.enhanceWithin();
	  });
	        $(document).bind( "pagechange", function( ) {
        $('table').wrap('<div class="tableCont"></div>');
        $('img').wrap('<div class="tableCont"></div>');
        $('.tableCont').enhanceWithin();
      } );
			// When the user scrolls down 20px from the top of the document, show the button
		window.onscroll = function() {scrollFunction()};
		function scrollFunction() {
		  if (document.body.scrollTop > 20 || document.documentElement.scrollTop > 20) {
			document.getElementById("myBtn").style.display = "block";
		  } else {
			document.getElementById("myBtn").style.display = "none";
		  }
		}
		// When the user clicks on the button, scroll to the top of the document
		function topFunction() {
		  document.body.scrollTop = 0; // For Safari
		  document.documentElement.scrollTop = 0; // For Chrome, Firefox, IE and Opera
		}</script>      
	

  

</head>
<body lang=EN-GB link=blue vlink=purple>

<div data-role="page">
	<div role="main" class="ui-content">
<div class=WordSection1>
<h1><span lang=EN-US>Acute Kidney Injury </span></h1>
<h2><i><span lang=EN-US>Executive summary</span></i></h2>
<h2><span lang=EN-US>Introduction</span></h2>
<p class=MsoNormal><span lang=EN-US>Acute kidney injury (AKI) is an abrupt
decline in renal function usually taking place over hours to days. It is
defined by a reduction in urine output and / or a laboratory diagnosis of a
decline in renal function i.e. increased serum creatinine (Cr) or reduced 
glomerular filtration rate (GFR). Acute kidney is a significant risk factor for
morbidity and mortality – a moderate elevation of serum creatinine is an
independent risk factor for mortality. The causes of AKI in adults are not
significantly different from the causes in children, however, different
criteria are used to determine the severity of AKI in each age group. AKI may
progress to chronic kidney disease(CKD) and may occur in the presence of CKD.
It is important to distinguish between the two conditions as interventions and
prognosis are very different. The difference is usually temporal.</span></p>
<h3><span lang=EN-US style='font-size:12.0pt;text-decoration:none'>Target User</span></h3>
<p class=MsoListParagraphCxSpFirst style='text-indent:-18.0pt'><span
lang=EN-US style='font-family:Symbol'>·<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-US>Doctors </span></p>
<p class=MsoListParagraphCxSpLast style='text-indent:-18.0pt'><span lang=EN-US
style='font-family:Symbol'>·<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-US>Nurses</span></p>
<h3><span lang=EN-US style='font-size:12.0pt;text-decoration:none'>Target area
of use </span></h3>
<p class=MsoListParagraphCxSpFirst style='text-indent:-18.0pt'><span
lang=EN-US style='font-family:Symbol'>·<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-US>Ward</span></p>
<p class=MsoListParagraphCxSpLast style='text-indent:-18.0pt'><span lang=EN-US
style='font-family:Symbol'>·<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-US>Outpatient department</span></p>
<h3><span lang=EN-US style='font-size:12.0pt;text-decoration:none'>Key areas of
focus </span></h3>
<p class=MsoNormal><span lang=EN-US>The main focus of this guideline is to
stimulate doctors to recognize and manage AKI promptly. It is necessary to
follow up the patients with AKI and those at risk of AKI to reduce morbidity.
Furosemide use in the management of AKI is restricted to patients with signs of
fluid overload.</span></p>
<h3><span lang=EN-US style='font-size:12.0pt;text-decoration:none'>Limitations </span></h3>
<h2><span lang=EN-US style='font-size:11.0pt;font-weight:normal'>Management of
stage 3 AKI (an indication for renal replacement therapy) is not available at
CSD. These patients must be referred to EFSTH. Patients at Keneba who are
suspected to have AKI should be referred for adequate management.</span></h2>
<p class=MsoNormal><span lang=EN-US style='font-size:10.0pt'>&nbsp;</span></p>
<p class=MsoNormal><span lang=EN-US>&nbsp;</span></p>
<span lang=EN-US style='font-size:11.0pt;font-family:"Arial","sans-serif"'><br
clear=all style='page-break-before:always'>
</span>
<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt'><b><span
lang=EN-US style='font-size:12.0pt'>&nbsp;</span></b></p>
<h2><span lang=EN-US>Common causes: </span></h2>
<p class=MsoNormal><span lang=EN-US>The following are common causes of AKI in
this region. </span></p>
<p class=MsoListParagraphCxSpFirst style='text-indent:-18.0pt'><span
lang=EN-US style='font-family:Symbol'>·<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-US>Gastroenteritis </span></p>
<p class=MsoListParagraphCxSpMiddle style='text-indent:-18.0pt'><span
lang=EN-US style='font-family:Symbol'>·<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-US>Sepsis</span></p>
<p class=MsoListParagraphCxSpMiddle style='text-indent:-18.0pt'><span
lang=EN-US style='font-family:Symbol'>·<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-US>Malaria </span></p>
<p class=MsoListParagraphCxSpMiddle style='text-indent:-18.0pt'><span
lang=EN-US style='font-family:Symbol'>·<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-US>Haemorrhage </span></p>
<p class=MsoListParagraphCxSpMiddle style='text-indent:-18.0pt'><span
lang=EN-US style='font-family:Symbol'>·<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-US>Glomerulonephritis, especially in children </span></p>
<p class=MsoListParagraphCxSpMiddle style='text-indent:-18.0pt'><span
lang=EN-US style='font-family:Symbol'>·<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-US>Use of nephrotoxins – NSAIDs, aminoglycosides,
ACEi / ARBs, diuretics overuse, metformin, herbal medications, contrast dyes</span></p>
<p class=MsoListParagraphCxSpMiddle style='text-indent:-18.0pt'><span
lang=EN-US style='font-family:Symbol'>·<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-US>Heart failure </span></p>
<p class=MsoListParagraphCxSpMiddle style='text-indent:-18.0pt'><span
lang=EN-US style='font-family:Symbol'>·<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-US>Liver failure </span></p>
<p class=MsoListParagraphCxSpLast style='text-indent:-18.0pt'><span lang=EN-US
style='font-family:Symbol'>·<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-US>Urinary tract obstruction - stones, tumours </span></p>
<h2><span lang=EN-US>Risk factors for AKI </span></h2>
<p class=MsoListParagraphCxSpFirst style='text-indent:-18.0pt'><span
lang=EN-US style='font-family:Symbol'>·<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-US>Patients older than 65 years of age</span></p>
<p class=MsoListParagraphCxSpMiddle style='text-indent:-18.0pt'><span
lang=EN-US style='font-family:Symbol'>·<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-US>CKD</span></p>
<p class=MsoListParagraphCxSpMiddle style='text-indent:-18.0pt'><span
lang=EN-US style='font-family:Symbol'>·<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-US>Heart failure</span></p>
<p class=MsoListParagraphCxSpMiddle style='text-indent:-18.0pt'><span
lang=EN-US style='font-family:Symbol'>·<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-US>Liver disease</span></p>
<p class=MsoListParagraphCxSpMiddle style='text-indent:-18.0pt'><span
lang=EN-US style='font-family:Symbol'>·<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-US>Diabetes</span></p>
<p class=MsoListParagraphCxSpMiddle style='text-indent:-18.0pt'><span
lang=EN-US style='font-family:Symbol'>·<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-US>Haematological malignancy</span></p>
<p class=MsoListParagraphCxSpMiddle style='text-indent:-18.0pt'><span
lang=EN-US style='font-family:Symbol'>·<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-US>History of AKI</span></p>
<p class=MsoListParagraphCxSpMiddle style='text-indent:-18.0pt'><span
lang=EN-US style='font-family:Symbol'>·<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-US>Neurological/cognitive impairment</span></p>
<p class=MsoListParagraphCxSpLast style='text-indent:-18.0pt'><span lang=EN-US
style='font-family:Symbol'>·<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-US>Reliance on carers for fluids </span></p>
<h2><span lang=EN-US>Presenting symptoms and signs</span></h2>
<p class=MsoListParagraphCxSpFirst style='text-indent:-18.0pt'><span
lang=EN-US style='font-family:Symbol'>·<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-US>Reduced urine volume or absent urine </span></p>
<p class=MsoListParagraphCxSpMiddle style='text-indent:-18.0pt'><span
lang=EN-US style='font-family:Symbol'>·<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-US>Features suggestive of uraemia including
epigastric pain, haematemesis, haematochezia, chest pain, confusion,
obtundation, loss of consciousness, increased somnolence, dyspnea, abnormal
bleeding and bruising, generalised body weakness</span></p>
<p class=MsoListParagraphCxSpLast style='text-indent:-18.0pt'><span lang=EN-US
style='font-family:Symbol'>·<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-US>Features of the underlying causes: fever,
vomiting, diarrhoea, haematuria</span></p>
<h2><span lang=EN-US>Examination findings</span></h2>
<p class=MsoNormal><span lang=EN-US>This includes features of AKI (oliguria or
anuria) as well as those of the underlying cause or complications.</span></p>
<p class=MsoListParagraphCxSpFirst style='text-indent:-18.0pt'><span
lang=EN-US style='font-family:Symbol'>·<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-US>Oliguria or anuria </span></p>
<p class=MsoListParagraphCxSpMiddle style='text-indent:-18.0pt'><span
lang=EN-US style='font-family:Symbol'>·<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-US>Fever or hypothermia </span></p>
<p class=MsoListParagraphCxSpMiddle style='text-indent:-18.0pt'><span
lang=EN-US style='font-family:Symbol'>·<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-US>Pallor </span></p>
<p class=MsoListParagraphCxSpMiddle style='text-indent:-18.0pt'><span
lang=EN-US style='font-family:Symbol'>·<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-US>Dehydration</span></p>
<p class=MsoListParagraphCxSpMiddle style='text-indent:-18.0pt'><span
lang=EN-US style='font-family:Symbol'>·<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-US>Jaundice </span></p>
<p class=MsoListParagraphCxSpLast style='text-indent:-18.0pt'><span lang=EN-US
style='font-family:Symbol'>·<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-US>Oedema </span></p>
<span lang=EN-US style='font-size:11.0pt;font-family:"Arial","sans-serif"'><br
clear=all style='page-break-before:always'>
</span>
<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt'><b><span
lang=EN-US style='font-size:12.0pt'>&nbsp;</span></b></p>
<h2><span lang=EN-US>Investigations</span></h2>
<p class=MsoListParagraphCxSpFirst style='text-indent:-18.0pt'><span
lang=EN-US style='font-family:Symbol'>·<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-US>Urinalysis</span></p>
<p class=MsoListParagraphCxSpMiddle style='text-indent:-18.0pt'><span
lang=EN-US style='font-family:Symbol'>·<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-US>Urine microscopy </span></p>
<p class=MsoListParagraphCxSpMiddle style='text-indent:-18.0pt'><span
lang=EN-US style='font-family:Symbol'>·<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-US>Serum electrolytes, urea, creatinine, calcium
and phosphate</span></p>
<p class=MsoListParagraphCxSpMiddle style='text-indent:-18.0pt'><span
lang=EN-US style='font-family:Symbol'>·<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-US>FBC and blood film</span></p>
<p class=MsoListParagraphCxSpLast style='text-indent:-18.0pt'><span lang=EN-US
style='font-family:Symbol'>·<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-US>Renal ultrasound</span></p>
<p class=MsoNormal><b><span lang=EN-US style='font-size:12.0pt'>Diagnosis of
AKI  </span></b></p>
<p class=MsoNormal><span lang=EN-US>The diagnosis of AKI is made if any<u> ONE</u>
of the following criteria is fulfilled:</span></p>
<p class=MsoListParagraphCxSpFirst style='text-indent:-18.0pt'><span
lang=EN-US style='font-family:Symbol'>·<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-US>Increase in Cr by 26.5 µmol/l within 48 hours;
or</span></p>
<p class=MsoListParagraphCxSpMiddle style='text-indent:-18.0pt'><span
lang=EN-US style='font-family:Symbol'>·<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-US>Increase in Cr ≥ 1.5 times baseline, which is
known or presumed to have occurred within the prior 7 days; or</span></p>
<p class=MsoListParagraphCxSpMiddle style='text-indent:-18.0pt'><span
lang=EN-US style='font-family:Symbol'>·<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-US>Urine volume of ˂ 0.5 ml/kg/h for 6 hours
(adults) or 8 hours (children); or</span></p>
<p class=MsoListParagraphCxSpLast style='text-indent:-18.0pt'><span lang=EN-US
style='font-family:Symbol'>·<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-US>25% of greater fall in eGFR in children within
past 7 days.</span></p>
<p class=MsoNormal><span lang=EN-US>The staging of AKI severity is determined
by creatinine levels in adults and by creatinine clearance in children as well
as urine output in both age groups </span></p>
<p class=MsoNormal><span lang=EN-US> </span></p>
<div class="tableCont">
  <table class=MsoTableGrid border=1 cellspacing=0 cellpadding=0 width=728
 style='width:546.05pt;margin-left:5pt;border-collapse:collapse;
 border:none'>
 <tr>
  <td width=56 rowspan=2 valign=top style='width:42.3pt;border:solid windowtext 1.5pt;
  padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal><b><span lang=EN-US>Stage </span></b></p>
  </td>
  <td width=289 colspan=2 valign=top style='width:216.6pt;border-top:solid windowtext 1.5pt;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.5pt;
  padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><b><span
  lang=EN-US>Children</span></b></p>
  </td>
  <td width=383 colspan=2 valign=top style='width:287.15pt;border:solid windowtext 1.5pt;
  border-left:none;padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><b><span
  lang=EN-US>Adults</span></b></p>
  </td>
 </tr>
 <tr>
  <td width=161 valign=top style='width:120.5pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.5pt;border-right:solid windowtext 1.0pt;
  padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal><b><span lang=EN-US>eGFR criteria</span></b></p>
  </td>
  <td width=128 valign=top style='width:96.1pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.5pt;border-right:solid windowtext 1.5pt;
  padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal><b><span lang=EN-US>Urine output criteria </span></b></p>
  </td>
  <td width=222 valign=top style='width:166.15pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.5pt;border-right:solid windowtext 1.0pt;
  padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal><b><span lang=EN-US>Creatinine criteria</span></b></p>
  </td>
  <td width=161 valign=top style='width:121.0pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.5pt;border-right:solid windowtext 1.5pt;
  padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal><b><span lang=EN-US>Urine output criteria</span></b></p>
  </td>
 </tr>
 <tr>
  <td width=56 valign=top style='width:42.3pt;border-top:none;border-left:solid windowtext 1.5pt;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.5pt;
  padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal><span lang=EN-US>1</span></p>
  </td>
  <td width=161 valign=top style='width:120.5pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal><span lang=EN-US>eGFR decreased by 25%</span></p>
  </td>
  <td width=128 valign=top style='width:96.1pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.5pt;
  padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal><span lang=EN-US>&lt; 0.5ml/kg/hr x 8 hours</span></p>
  </td>
  <td width=222 valign=top style='width:166.15pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal><span lang=EN-US>1.5 – 1.9 times base line Cr OR  </span></p>
  <p class=MsoNormal><span lang=EN-US>Cr ≥ 26.5µmol from base line</span></p>
  </td>
  <td width=161 valign=top style='width:121.0pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.5pt;
  padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal><span lang=EN-US>&lt; 0.5 ml/kg/hr x 6 hours </span></p>
  </td>
 </tr>
 <tr>
  <td width=56 valign=top style='width:42.3pt;border-top:none;border-left:solid windowtext 1.5pt;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.5pt;
  padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal><span lang=EN-US>2</span></p>
  </td>
  <td width=161 valign=top style='width:120.5pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal><span lang=EN-US>eGFR decreased by 50%</span></p>
  </td>
  <td width=128 valign=top style='width:96.1pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.5pt;
  padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal><span lang=EN-US>&lt;0.5ml/kg/hr x16 hours</span></p>
  </td>
  <td width=222 valign=top style='width:166.15pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal><span lang=EN-US>2.0-2.9 times baseline Cr</span></p>
  </td>
  <td width=161 valign=top style='width:121.0pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.5pt;
  padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal><span lang=EN-US>&lt;0.5 ml/kg/hr x12 hours</span></p>
  </td>
 </tr>
 <tr>
  <td width=56 valign=top style='width:42.3pt;border:solid windowtext 1.5pt;
  border-top:none;padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal><span lang=EN-US>3</span></p>
  </td>
  <td width=161 valign=top style='width:120.5pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.5pt;border-right:solid windowtext 1.0pt;
  padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal><span lang=EN-US>eGFR decreased by 75% OR</span></p>
  <p class=MsoNormal><span lang=EN-US>eGFR &lt; 35 ml/min/1.73m<sup>2</sup></span></p>
  </td>
  <td width=128 valign=top style='width:96.1pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.5pt;border-right:solid windowtext 1.5pt;
  padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal><span lang=EN-US>&lt;0.3 ml/kg/hr x 24 hours OR anuria
  (≤100ml) for 12 hours</span></p>
  </td>
  <td width=222 valign=top style='width:166.15pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.5pt;border-right:solid windowtext 1.0pt;
  padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal><span lang=EN-US>≥ 3.0 times baseline Cr </span></p>
  <p class=MsoNormal><span lang=EN-US> OR</span></p>
  <p class=MsoNormal><span lang=EN-US>Cr ≥ 353.6µmol/L</span></p>
  <p class=MsoNormal><span lang=EN-US>OR </span></p>
  <p class=MsoNormal><span lang=EN-US>Initiation of renal replacement therapy </span></p>
  </td>
  <td width=161 valign=top style='width:121.0pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.5pt;border-right:solid windowtext 1.5pt;
  padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal><span lang=EN-US>&lt;0.3 ml/kg/hr x 24 hours or anuria
  (≤100 ml) for 12 hours</span></p>
  </td>
 </tr>
</table>
</div>
<p class=MsoNormal><span lang=EN-US>&nbsp;</span></p>
<p class=MsoNormal><span lang=EN-US>For children, the eGFR is calculated using
the Bedside Schwartz formula which can be found on this link <a
href="http://nephron.com/bedside_peds_nic.cgi">http://nephron.com/bedside_peds_nic.cgi</a>.</span></p>
<span lang=EN-US style='font-size:11.0pt;font-family:"Arial","sans-serif"'><br
clear=all style='page-break-before:always'>
</span>
<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt'><b><span
lang=EN-US style='font-size:12.0pt'>&nbsp;</span></b></p>
<h2><span lang=EN-US>Management </span></h2>
<p class=MsoNormal><span lang=EN-US>Management of AKI is similar for both
adults and children </span></p>
<h3><span lang=EN-US>Patients at risk:</span></h3>
<p class=MsoNormal><span lang=EN-US>Serum creatinine levels should be done at
baseline and  this should be repeated periodically. While on admission, creatinine
levels should be done at least on a weekly basis (more often depending on the
patient’s clinical status). Urine output should be monitored throughout
admission. </span></p>
<h3><span lang=EN-US>Conservative management: </span></h3>
<p class=MsoListParagraphCxSpFirst style='text-indent:-18.0pt'><span
lang=EN-US style='font-family:Symbol'>·<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-US>Treat underlying cause e.g. antibiotics for
sepsis, antimalarials for malaria etc.</span></p>
<p class=MsoListParagraphCxSpMiddle style='text-indent:-18.0pt'><span
lang=EN-US style='font-family:Symbol'>·<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-US>Replace fluid losses (insensible water loss plus
fluid loss from vomiting or diarrhea) with colloids, preferably containing
saline.</span></p>
<p class=MsoListParagraphCxSpMiddle style='text-indent:-18.0pt'><span
lang=EN-US style='font-family:Symbol'>·<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-US>Monitor input and output. Use urethral catheter
only if it will be difficult to estimate urine volume or if a urethral
obstruction is suspected. </span></p>
<p class=MsoListParagraphCxSpMiddle style='text-indent:-18.0pt'><span
lang=EN-US style='font-family:Symbol'>·<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-US>Ensure patient is feeding well: High caloric
intake with low to normal protein. </span></p>
<p class=MsoListParagraphCxSpMiddle style='text-indent:-18.0pt'><span
lang=EN-US style='font-family:Symbol'>·<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-US>Manage electrolyte disturbances such as
hyperkalaemia and metabolic acidosis using the guidelines on the management of
electrolyte disturbances.</span></p>
<p class=MsoListParagraphCxSpLast style='text-indent:-18.0pt'><span lang=EN-US
style='font-family:Symbol'>·<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><u><span lang=EN-US>Note</span></u><span lang=EN-US>: The use of
diuretics is restricted to conditions in which there is fluid overload e.g.
peripheral and pulmonary oedema. They should not be used routinely. </span></p>
<h3><span lang=EN-US>Indications for renal replacement therapy (referral to
EFSTH):</span></h3>
<p class=MsoNormal><b><span lang=EN-US>Biochemical </span></b></p>
<p class=MsoListParagraphCxSpFirst style='text-indent:-18.0pt'><span
lang=EN-US style='font-family:Symbol'>·<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-US>Refractory hyperkalaemia of  ≥ 6.5 mmol/L or 6 mmol/L
with ECG changes or a daily rise of 1 mmol/L/ day </span></p>
<p class=MsoListParagraphCxSpMiddle style='text-indent:-18.0pt'><span
lang=EN-US style='font-family:Symbol'>·<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-US>Refractory metabolic acidosis : Bicarbonate
levels ≤ 12 mmol/L </span></p>
<p class=MsoListParagraphCxSpMiddle style='text-indent:-18.0pt'><span
lang=EN-US style='font-family:Symbol'>·<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-US>Urea level of &gt; 25 mmol/L or increase of
&gt;10 mmol/L/day </span></p>
<p class=MsoListParagraphCxSpLast style='text-indent:-18.0pt'><span lang=EN-US
style='font-family:Symbol'>·<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-US>Stage 3 AKI (Serum creatinine ≥ 353.6 µmol/L) or
daily rise of ≥ 100 mmol/L/ day </span></p>
<p class=MsoNormal><b><span lang=EN-US>Clinical </span></b></p>
<p class=MsoListParagraphCxSpFirst style='text-indent:-18.0pt'><span
lang=EN-US style='font-family:Symbol'>·<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-US>Refractory pulmonary oedema</span></p>
<p class=MsoListParagraphCxSpMiddle style='text-indent:-18.0pt'><span
lang=EN-US style='font-family:Symbol'>·<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-US>Uraemic gastritis with persistent symptoms</span></p>
<p class=MsoListParagraphCxSpMiddle style='text-indent:-18.0pt'><span
lang=EN-US style='font-family:Symbol'>·<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-US>Uraemic pericarditis</span></p>
<p class=MsoListParagraphCxSpMiddle style='text-indent:-18.0pt'><span
lang=EN-US style='font-family:Symbol'>·<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-US>Uraemic encephalopathy </span></p>
<p class=MsoListParagraphCxSpLast style='text-indent:-18.0pt'><span lang=EN-US
style='font-family:Symbol'>·<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-US>Bleeding diathesis </span></p>
<h3><span lang=EN-US>Follow up:</span></h3>
<p class=MsoListParagraphCxSpFirst style='text-indent:-18.0pt'><span
lang=EN-US style='font-family:Symbol'>·<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-US>Counsel patient on the prognosis of AKI and the
need for follow up care. </span></p>
<p class=MsoListParagraphCxSpMiddle style='text-indent:-18.0pt'><span
lang=EN-US style='font-family:Symbol'>·<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-US>Serum creatinine levels should be measured at
least 90 days after recovery from AKI. Monitoring can be as frequent as monthly
</span></p>
<p class=MsoListParagraphCxSpLast style='text-indent:-18.0pt'><span lang=EN-US
style='font-family:Symbol'>·<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-US>Follow up in clinic may be extended to the next
2-3 years to check for progression of the disease, even if creatinine levels
are normal and stabilised. </span></p>
<span lang=EN-US style='font-size:11.0pt;font-family:"Arial","sans-serif"'><br
clear=all style='page-break-before:always'>
</span>
<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt'><b><span
lang=EN-US style='font-size:12.0pt'>&nbsp;</span></b></p>
<h2><span lang=EN-US>Key Issues for Nursing care</span></h2>
<p class=MsoListParagraphCxSpFirst style='text-indent:-18.0pt'><span
lang=EN-US style='font-family:Symbol'>·<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-US>Strict monitoring of patient’s input and output
on the fluid balance chart with escalation of care where necessary.</span></p>
<p class=MsoListParagraphCxSpMiddle style='text-indent:-18.0pt'><span
lang=EN-US style='font-family:Symbol'>·<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-US>Ensure adherence to the management protocol<b>.</b></span></p>
<p class=MsoListParagraphCxSpLast style='text-indent:-18.0pt'><span lang=EN-US
style='font-size:12.0pt;font-family:Symbol'>·<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-US>Restrict potassium-rich foods e.g. bananas, oranges,
cooked spinach and potatoes.</span></p>
<h2><span lang=EN-US>References</span></h2>
<p class=MsoNormal><span lang=EN-US style='font-size:10.0pt'>KDIGO A. K. I.
Work Group (2012). KDIGO clinical practice guideline for acute kidney injury.
Kidney Int Suppl, 2(1), 1-138. </span></p>
<p class=MsoNormal><span lang=EN-US style='font-size:10.0pt'>Soler, Y. A.,
Nieves-Plaza, M., Prieto, M., García-De Jesús, R., &amp; Suárez-Rivera, M.
(2013). pRIFLE (Pediatric Risk, Injury, Failure, Loss, End Stage Renal Disease)
score identifies Acute Kidney Injury and predicts mortality in critically ill
children: a prospective study. Pediatric critical care medicine: a journal of
the Society of Critical Care Medicine and the World Federation of Pediatric
Intensive and Critical Care Societies, 14(4), e189.</span></p>
<p class=MsoNormal><span lang=EN-US><a
href="https://www.nice.org.uk/guidance/cg169/evidence/acute-kidney-injury-full-guideline-pdf-191530621"><span
style='font-size:10.0pt'>https://www.nice.org.uk/guidance/cg169/evidence/acute-kidney-injury-full-guideline-pdf-191530621</span></a></span></p>
<p class=MsoNormal><span lang=EN-US style='font-size:10.0pt'>Rahman, M., Shad,
F., &amp; Smith, M. C. (2012). Acute kidney injury: a guide to diagnosis and
management. American family physician, 86(7).</span></p>
<div class="tableCont">
  <table class=MsoNormalTable border=1 cellspacing=0 cellpadding=0
 style='border-collapse:collapse;border:none'>
 <tr style='height:1.0pt'>
  <td width=143 valign=bottom style='width:106.95pt;border:solid windowtext 1.0pt;
  padding:0cm 5.4pt 0cm 5.4pt;height:1.0pt'>
  <p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt'><b><span
  lang=EN-US>Written by:</span></b></p>
  </td>
  <td width=241 valign=bottom style='width:181.1pt;border:solid windowtext 1.0pt;
  border-left:none;padding:0cm 5.4pt 0cm 5.4pt;height:1.0pt'>
  <p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt'><span
  lang=EN-US>Orighomisan Agboghoroma</span></p>
  </td>
  <td width=191 valign=bottom style='width:143.45pt;border:solid windowtext 1.0pt;
  border-left:none;padding:0cm 5.4pt 0cm 5.4pt;height:1.0pt'>
  <p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt'><span
  lang=EN-US>Date: 04 April 2019</span></p>
  </td>
 </tr>
 <tr style='height:1.0pt'>
  <td width=143 valign=bottom style='width:106.95pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0cm 5.4pt 0cm 5.4pt;height:1.0pt'>
  <p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt'><b><span
  lang=EN-US>Reviewed by:</span></b></p>
  </td>
  <td width=241 valign=bottom style='width:181.1pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0cm 5.4pt 0cm 5.4pt;height:1.0pt'>
  <p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt'><span
  lang=EN-US>Karen Forrest</span></p>
  </td>
  <td width=191 valign=bottom style='width:143.45pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0cm 5.4pt 0cm 5.4pt;height:1.0pt'>
  <p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt'><span
  lang=EN-US>Date: 07 May 2019</span></p>
  </td>
 </tr>
 <tr style='height:1.0pt'>
  <td width=143 valign=bottom style='width:106.95pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0cm 5.4pt 0cm 5.4pt;height:1.0pt'>
  <p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt'><b><span
  lang=EN-US>Version:</span></b></p>
  </td>
  <td width=241 valign=bottom style='width:181.1pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0cm 5.4pt 0cm 5.4pt;height:1.0pt'>
  <p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt'><b><span
  lang=EN-US>Change history:</span></b></p>
  </td>
  <td width=191 valign=bottom style='width:143.45pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0cm 5.4pt 0cm 5.4pt;height:1.0pt'>
  <p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt'><b><span
  lang=EN-US>Review due date:</span></b></p>
  </td>
 </tr>
 <tr style='height:1.0pt'>
  <td width=143 valign=bottom style='width:106.95pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0cm 5.4pt 0cm 5.4pt;height:1.0pt'>
  <p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt'><span
  lang=EN-US>1.0</span></p>
  </td>
  <td width=241 valign=bottom style='width:181.1pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0cm 5.4pt 0cm 5.4pt;height:1.0pt'>
  <p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt'><span
  lang=EN-US>New document</span></p>
  </td>
  <td width=191 valign=bottom style='width:143.45pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0cm 5.4pt 0cm 5.4pt;height:1.0pt'>
  <p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt'><span
  lang=EN-US>31 May 2021</span></p>
  </td>
 </tr>
 <tr style='height:1.0pt'>
  <td width=143 valign=bottom style='width:106.95pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0cm 5.4pt 0cm 5.4pt;height:1.0pt'>
  <p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt'><span
  lang=EN-US>Review Comments (<i>if applicable)</i></span></p>
  </td>
  <td width=241 valign=bottom style='width:181.1pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0cm 5.4pt 0cm 5.4pt;height:1.0pt'>
  <p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt'><span
  lang=EN-US>&nbsp;</span></p>
  </td>
  <td width=191 valign=bottom style='width:143.45pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0cm 5.4pt 0cm 5.4pt;height:1.0pt'>
  <p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt'><b><span
  lang=EN-US>&nbsp;</span></b></p>
  </td>
 </tr>
</table>
</div>
<p class=MsoNormal><span style='color:black'>&nbsp;</span></p>
</div>
</div><!-- /content -->

</div>

</body>
</html>
